Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Illumina (NASDAQ: ILMN) announced significant changes to its Board of Directors. Dr. Scott Gottlieb, who has served on the Board since 2020, has been elected as non-executive Chair. Additionally, Keith Meister, founder and Chief Investment Officer of Corvex Management, will join the Board on March 28, 2025.
Stephen MacMillan, who joined the Board in June 2023, will retire ahead of the upcoming annual shareholder meeting. Dr. Gottlieb expressed commitment to advancing the company's mission and driving profitable growth, while Meister voiced confidence in Illumina's strategy to expand its role in genomics and deliver shareholder value.
Illumina (NASDAQ: ILMN) ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. Il Dr. Scott Gottlieb, che fa parte del Consiglio dal 2020, è stato eletto presidente non esecutivo. Inoltre, Keith Meister, fondatore e Chief Investment Officer di Corvex Management, entrerà a far parte del Consiglio il 28 marzo 2025.
Stephen MacMillan, che si è unito al Consiglio a giugno 2023, si ritirerà prima della prossima riunione annuale degli azionisti. Il Dr. Gottlieb ha espresso il suo impegno per promuovere la missione dell'azienda e guidare una crescita redditizia, mentre Meister ha espresso fiducia nella strategia di Illumina per ampliare il suo ruolo nella genomica e fornire valore agli azionisti.
Illumina (NASDAQ: ILMN) anunció cambios significativos en su Junta Directiva. El Dr. Scott Gottlieb, quien ha sido miembro de la Junta desde 2020, ha sido elegido presidente no ejecutivo. Además, Keith Meister, fundador y Chief Investment Officer de Corvex Management, se unirá a la Junta el 28 de marzo de 2025.
Stephen MacMillan, quien se unió a la Junta en junio de 2023, se retirará antes de la próxima reunión anual de accionistas. El Dr. Gottlieb expresó su compromiso con avanzar en la misión de la empresa y fomentar un crecimiento rentable, mientras que Meister manifestó confianza en la estrategia de Illumina para ampliar su papel en la genómica y proporcionar valor a los accionistas.
일루미나 (NASDAQ: ILMN)는 이사회에 중요한 변화를 발표했습니다. 스콧 고틀립 박사는 2020년부터 이사회에서 활동해 왔으며, 비상임 의장으로 선출되었습니다. 또한, 키스 마이스터는 코르벡스 매니지먼트의 창립자이자 최고 투자 책임자로, 2025년 3월 28일 이사회에 합류할 예정입니다.
2023년 6월 이사회에 합류한 스티븐 맥밀란은 다가오는 연례 주주 총회 전에 은퇴할 것입니다. 고틀립 박사는 회사의 사명을 발전시키고 수익성 있는 성장을 이끌겠다는 의지를 표명했으며, 마이스터는 일루미나의 전략에 대한 신뢰를 나타내어 유전체학에서의 역할을 확장하고 주주 가치를 제공할 것이라고 전했습니다.
Illumina (NASDAQ: ILMN) a annoncé des changements significatifs au sein de son Conseil d'Administration. Le Dr. Scott Gottlieb, qui siège au Conseil depuis 2020, a été élu président non exécutif. De plus, Keith Meister, fondateur et Chief Investment Officer de Corvex Management, rejoindra le Conseil le 28 mars 2025.
Stephen MacMillan, qui a rejoint le Conseil en juin 2023, prendra sa retraite avant la prochaine assemblée générale annuelle des actionnaires. Le Dr. Gottlieb a exprimé son engagement à faire avancer la mission de l'entreprise et à favoriser une croissance rentable, tandis que Meister a exprimé sa confiance dans la stratégie d'Illumina pour élargir son rôle en génomique et offrir de la valeur aux actionnaires.
Illumina (NASDAQ: ILMN) hat bedeutende Änderungen in seinem Vorstand angekündigt. Dr. Scott Gottlieb, der seit 2020 im Vorstand sitzt, wurde zum nicht-executive Vorsitzenden gewählt. Zudem wird Keith Meister, Gründer und Chief Investment Officer von Corvex Management, am 28. März 2025 in den Vorstand eintreten.
Stephen MacMillan, der im Juni 2023 dem Vorstand beigetreten ist, wird vor der bevorstehenden jährlichen Hauptversammlung der Aktionäre zurücktreten. Dr. Gottlieb bekundete sein Engagement, die Mission des Unternehmens voranzutreiben und profitables Wachstum zu fördern, während Meister Vertrauen in Illuminas Strategie äußerte, seine Rolle in der Genomik zu erweitern und den Aktionärswert zu steigern.
- Appointment of experienced healthcare leader Dr. Scott Gottlieb as Board Chair
- Addition of Keith Meister brings valuable investor perspective and focus on shareholder value creation
- Board restructuring signals renewed focus on profitable growth and value creation
- Relatively short tenure of departing board member MacMillan (less than 2 years) may indicate board instability
Stephen MacMillan to retire from the Board
"I'm honored to accept this role at Illumina, a company at the forefront of our rapidly evolving industry, whose groundbreaking innovations continue to transform patient opportunities and shape the field of genomics," Dr. Gottlieb said. "I extend our gratitude to Steve for his dedication and commitment to Illumina, and I look forward to continuing to collaborate with the board and management team to advance the company's mission and to drive profitable growth. We also welcome to the board Keith Meister, who brings experience as an investor in the field of genomics along with a strong record of supporting value creation for shareholders."
Mr. MacMillan commented, "I am pleased with what Illumina has accomplished in advancing genomics and fostering groundbreaking innovations that have shaped our field, and I am grateful to the board for entrusting me with the opportunity to contribute to this remarkable company. I leave with great confidence in the board and the management team. Their collective vision, leadership, and deep commitment to scientific progress give me every reason to believe they'll continue—and indeed amplify—the transformative work we have set in motion."
"I look forward to working with Illumina's Board and strong management team," Mr. Meister said. "Illumina has the right strategy to drive the expansion of its role in helping to shape the field of genomics and expand the application of these technologies for patient care, and I'm confident in Illumina's ability to accelerate revenue growth and deliver value for shareholders."
About Scott Gottlieb, MD
Scott Gottlieb was appointed to Illumina's Board in February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the
About Keith Meister
Keith Meister is Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010. Mr. Meister currently serves on the boards of directors for MGM Resorts, GeneDx and Vestis. He is Chairman of the board of directors of the Harlem Children's Zone and a member of the board of trustees for the American Museum of Natural History.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content:https://www.prnewswire.com/news-releases/illumina-board-of-directors-elects-dr-scott-gottlieb-chair-keith-meister-to-join-board-of-directors-302410365.html
SOURCE Illumina, Inc.
FAQ
Who is the new Board Chair of Illumina (ILMN) as of March 2025?
When will Keith Meister join Illumina's (ILMN) Board of Directors?
Why is Stephen MacMillan leaving Illumina's (ILMN) Board?
What experience does Keith Meister bring to Illumina's (ILMN) Board?
